Antimicrobial and antimotility agent use in persons with shiga toxin-producing Escherichia coli O157 infection in FoodNet Sites

Clin Infect Dis. 2011 May;52(9):1130-2. doi: 10.1093/cid/cir087.

Abstract

Antimicrobial and antimotility agents are not recommended for the treatment of Shiga toxin-producing Escherichia coli O157 infection. In our study, many persons with Shiga toxin-producing E. coli O157 infection took antimicrobial (62%) and antimotility agents (32%); 43 (29%) of 146 reported commencing antimicrobial treatment after laboratory confirmation. Efforts are needed to promote practice guidelines.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Anti-Bacterial Agents / adverse effects*
  • Anti-Bacterial Agents / therapeutic use
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Diphenoxylate / adverse effects
  • Diphenoxylate / therapeutic use
  • Escherichia coli Infections / complications
  • Escherichia coli Infections / drug therapy*
  • Escherichia coli Infections / epidemiology
  • Escherichia coli Infections / microbiology
  • Escherichia coli O157 / drug effects*
  • Hemolytic-Uremic Syndrome / epidemiology
  • Hemolytic-Uremic Syndrome / etiology*
  • Hemolytic-Uremic Syndrome / microbiology
  • Humans
  • Loperamide / adverse effects
  • Loperamide / therapeutic use
  • Parasympatholytics / adverse effects*
  • Parasympatholytics / therapeutic use
  • Population Surveillance / methods
  • Practice Patterns, Physicians'
  • Shiga Toxins / biosynthesis*
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Parasympatholytics
  • Shiga Toxins
  • Loperamide
  • Diphenoxylate